Adipotide (FTPP)
Also known as: Adipotide, FTPP
Adipotide is an experimental peptidomimetic studied in animals for targeted destruction of the blood supply feeding white fat tissue.
Last updated
Mechanism of Action
Adipotide (also called FTPP or prohibitin-targeting peptide-1) is a fusion of a CKGGRAKDC homing sequence that binds prohibitin on the surface of white adipose vasculature, linked to a KLAKLAK pro-apoptotic sequence. The homing peptide directs the construct selectively to endothelial cells of fat-supplying capillaries, where the membrane-disrupting KLAKLAK domain triggers mitochondrial apoptosis. Loss of this vasculature starves white adipose tissue, leading to fat resorption and weight loss in preclinical models.
- Half-life
- Short; estimated under a few hours in circulation
- Administration Routes
- subcutaneous
- Research Status
- Preclinical
Reported Benefits
- Produced rapid fat-mass loss in primate studies
- Targets adipose vasculature rather than appetite pathways
- Associated with improved insulin sensitivity in animal models
- Selective homing to white-fat blood supply
Potential Side Effects
- Renal toxicity observed in primate studies (dose-limiting)
- Dehydration and changes in kidney function
- No established human safety profile
- Potential injection-site reactions
Common Dosing
For research use only: primate studies used roughly 0.43 mg/kg subcutaneously daily for short cycles. No validated human dosing exists. Not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Any pre-existing renal impairment
- Pregnancy and breastfeeding
- Use without clinical monitoring of kidney function
No documented stacking partners for Adipotide (FTPP) yet.